Chapter 43 — Quiz

DataField.Dev

Chapter 43 — Quiz

Enhancement Outside the Clinic

Twenty-two items. A mix of recall, reasoning, and application. Several questions have deliberately attractive wrong answers drawn from arguments that circulate widely; if one of those looks obviously correct to you, that is worth noticing before you check the key.

Answer all twenty-two before opening the key.

1. Which four things does §43.1 identify as supplied by clinical medicine and removed by enhancement?

(a) A prescription, a pharmacy, an insurer, and a follow-up appointment
(b) A diagnosis, an indication, a clinician with a duty, and an individualized risk-benefit judgment
(c) A trial, a regulator, a label, and a warning
(d) Consent, cost control, monitoring, and legality

2. A rating in this book attaches to:

(a) a molecule
(b) a class of molecules
(c) a claim with a stated population and endpoint
(d) a manufacturer

3. The chapter rates the claim "peptide enhancement produces meaningful performance benefit in healthy trained adults" as:

(a) ✅
(b) ⚠️
(c) ❌
(d) 🔬

4. The primary reason for that rating is:

(a) that enhancement is unethical
(b) that outcome evidence in healthy trained adults is absent, and trials in disease populations showed gains in mass without gains in function
(c) that the compounds are illegal in most jurisdictions
(d) that the mechanism is implausible

5. A positional good is one whose value depends on:

(a) its cost
(b) its scarcity in absolute terms
(c) your rank relative to others rather than your absolute level
(d) how long its effects last

6. In the coercion structure of §43.5, which step is described as "the hinge of the argument"?

(a) Step 1, the contest being positional
(b) Step 2, early adopters gaining an advantage
(c) Step 4, non-adopters adopting to avoid a loss rather than to seek a gain
(d) Step 5, the advantage being competed away

7. At full adoption (step 5), the competitive benefit of an enhancement is:

(a) maximized, because everyone is performing better
(b) roughly eliminated, while the cost and risk are borne by everyone
(c) transferred to the earliest adopters permanently
(d) unchanged from step 2

8. The coercion argument applies most weakly when:

(a) performance is observable and continuously compared
(b) the benefit is largely private and absolute, with no competitive component
(c) the enhancement is cheap and easy to conceal
(d) the population is young and harms are delayed

9. Why does the chapter say sport is a useful "natural experiment"?

(a) Because athletes are physiologically representative of the general population
(b) Because it is the only domain that has built an explicit, enforced, adjudicated answer, so the costs and achievements of such an answer are observable
(c) Because doping data provide reliable prevalence estimates for other domains
(d) Because anti-doping rules are based on randomized trials

10. Which of the following is identified as a cost of sport's enforced answer?

(a) A published, appealable standard known in advance
(b) A mechanism allowing a sick athlete to receive needed treatment
(c) Unintentional violations arising from contaminated supply, landing on athletes who did nothing recognizable as cheating
(d) A body of adjudicated decisions giving the rule meaning

11. The therapeutic use exemption is significant to this chapter because it:

(a) proves that all enhancement should be permitted
(b) institutionally concedes that the same molecule is therapy or enhancement depending on the situation of the person receiving it
(c) shows that testing is unnecessary
(d) eliminates inequality in access to treatment

12. Regarding peptide use in workplace contexts, the chapter states that:

(a) it is widespread, at approximately known rates
(b) it is rare and declining
(c) it is not well characterized, and no defensible prevalence figure is available
(d) it is confined to a small number of industries

13. The chapter's treatment of military and occupational contexts is deliberately abstract because:

(a) the subject is uninteresting
(b) specific contemporary claims cannot be sourced to the standard the book applies elsewhere
(c) no such contexts exist
(d) the coercion argument does not apply there

14. "Voluntary" is said to mean something different inside a hierarchy primarily because:

(a) hierarchies always compel their members
(b) the consequences of declining differ when the offer comes from a party with authority over your future, even absent any threat
(c) members of hierarchies are less capable of informed consent
(d) hierarchies do not permit refusal

15. Which is the strongest form of the level-playing-field argument?

(a) That enhancement is inevitable, so prohibition is pointless
(b) That prohibition relocates supply to an unregulated market with documented failures of identity, concentration, and sterility, which a sanctioned regime would address
(c) That everyone at the top is already using something
(d) That enhancement is a private matter

16. The chapter's deepest objection to the level-playing-field argument is that it:

(a) is illegal in most countries
(b) would be expensive to implement
(c) does not address coercion at all, since the coercion structure runs on adoption rather than legality
(d) has no supporters

17. The claim "sanctioned, supervised enhancement is safer than a black market" is rated:

(a) ✅
(b) ⚠️
(c) ❌
(d) 🔬

18. The chapter declines to rate "enhancement is inevitable" because:

(a) the answer is obviously yes
(b) the answer is obviously no
(c) it has no defined population, no endpoint, and no falsifier, and is therefore outside the rating system's competence
(d) rating social claims is forbidden

19. The observation that "where risk and benefit separate, the party bearing the risk is systematically under-compensated" is presented as:

(a) a moral principle
(b) an observation from economics that does not depend on a moral premise
(c) a finding from a randomized trial
(d) a legal doctrine

20. Which of the following does not appear in the chapter's list of what medical supervision provides?

(a) Baselines measured before administration
(b) Recognizing tolerance rather than escalating into it
(c) Guaranteed absence of adverse events
(d) Someone to call

21. According to §43.9, which condition cannot be satisfied by research, policy, or better information — because it is a property of the contest rather than of the person, the compound, or the seller?

(a) Established safety at the relevant exposure
(b) Genuine informed consent
(c) Absence of coercive structure
(d) Reversibility

22. Which single statement best captures the chapter's overall position?

(a) Enhancement is unethical and should be prohibited
(b) Enhancement is a private choice and objections to it are squeamishness
(c) Whether enhancement is permissible is a values question the book does not settle, but the empirical claims embedded in every position can and should be evaluated
(d) The pharmacology settles the ethics

Answer key

**1 — (b).** A diagnosis, an indication, a clinician with a duty, and an individualized risk-benefit judgment. Option (a) lists administrative machinery, which can be present in enhancement contexts and supplies none of the four. **2 — (c).** A claim with a stated population and endpoint. This is rule 1, and it is the rule that explains how the same molecule can be rated differently in Chapter 14 and here. **3 — (c).** ❌. **4 — (b).** Note what is *not* the reason. Rule 4 forbids downgrading on distaste, so (a) would be a misuse of the system; legality (c) is irrelevant to an evidence rating; and rule 3 means an implausible mechanism (d) would not by itself justify a rating either — mechanism arguments do not move ratings in either direction. **5 — (c).** Rank rather than absolute level. **6 — (c).** Step 4. This is where the adopter's reason changes from *seeking a gain* to *avoiding a loss*, even though the action is identical from the outside. **7 — (b).** Roughly eliminated, with the cost and risk retained by everyone. This is the dissipation result, and it is the same structure as an arms race. **8 — (b).** Where the benefit is private and absolute, step 3 never happens — nobody's standing falls because of someone else's improvement — so no coercive structure forms. **9 — (b).** Sport is the only domain with an enforced answer, which makes the consequences of having one observable rather than hypothetical. Note that (a) and (c) are both generalizations the chapter explicitly warns against. **10 — (c).** The other three options are all listed as *achievements*. Contaminated-supply violations are a cost, and Chapter 34's account of the unregulated supply chain makes them predictable. **11 — (b).** The exemption is §43.1's point made operational: prohibited *unless there is a patient*. Option (d) inverts one of the chapter's findings — the exemption mechanism has its own equity problem, since documentation is unequally available. **12 — (c).** Not well characterized. The well-documented literature on workplace pharmacological enhancement concerns stimulants, and even there prevalence estimates vary widely enough that a single number would misrepresent them. **13 — (b).** The alternative to abstraction was invention, and Chapter 5's rules apply to the author as well as to everyone else. **14 — (b).** The point is structural and survives complete good faith on all sides. Options (a) and (d) overstate it in a way the chapter specifically avoids. **15 — (b).** This is the harm-reduction version, and it is the strongest form because it rests on documented properties of the unregulated market rather than on prediction. Options (a) and (c) are arguments the chapter treats critically elsewhere. **16 — (c).** It answers a safety question with a safety solution while leaving the freedom question untouched — and a sanctioned regime would likely *increase* adoption, which drives the coercion structure faster. **17 — (b).** ⚠️. Plausible, supported by general harm-reduction reasoning, untested for these compounds, and answering a narrower question than it is usually deployed against. **18 — (c).** No population, no endpoint, no falsifier. If adoption rises the claim is confirmed; if it falls, the claim becomes "not yet" — and a claim confirmed by every outcome is not a prediction. **19 — (b).** It is an externality argument, and it holds regardless of what you concluded about the ethics. That independence is the reason the chapter bothers to make it. **20 — (c).** Supervision manages known risks; it cannot guarantee their absence, and it does considerably less for risks that have never been characterized. **21 — (c).** Absence of coercive structure. It is a property of the contest, so no individual participant can satisfy it by being careful — which is why the chapter is named after the coercion question rather than the safety question. **22 — (c).** The book takes no side on permissibility and insists that the embedded empirical claims be evaluated. Both halves matter; (a) and (b) each drop one of them.